CDTs vs. Botanical Terpenes: Why the Source Matters

Not all terpenes are created equal. The cannabis industry uses the term loosely — and that ambiguity costs operators money, undermines product quality, and misleads consumers who are increasingly sophisticated about what they're buying.

The core distinction is simple: cannabis-derived terpenes (CDTs) come from the cannabis plant itself. Botanical terpenes come from other plants — lavender, citrus, pine, hops — and are blended to approximate cannabis flavor profiles. They are fundamentally different products.

What Are Botanical Terpenes?

Botanical terpenes are isolated from non-cannabis plant sources and combined to mimic the terpene profiles of popular cannabis strains. Myrcene from hops, limonene from citrus peel, linalool from lavender — individually pure, but assembled into something that never existed in nature.

They're widely used because they're inexpensive, consistent, and easy to source at scale. For operators focused purely on cost, they're an attractive option. But the product that results is an approximation — a reconstruction, not a reproduction.

What Are Cannabis-Derived Terpenes?

CDTs are extracted directly from cannabis biomass — capturing the actual terpene profile produced by that specific cultivar. The result includes not just the major terpenes that laboratories report, but the full spectrum of minor terpenes and aromatic compounds unique to that strain.

This is important because cannabis terpene profiles are extraordinarily complex. A single cultivar may contain dozens of terpene compounds in specific ratios that no botanical blend can replicate. That complexity is precisely what produces the distinctive character of a true strain-specific product.

The Quality Gap

The difference shows up in lab reports, in consumer experience, and increasingly in regulatory frameworks. Some markets now require disclosure of terpene sourcing. Consumers who read labels are beginning to distinguish between "natural terpenes" (which can legally mean botanical) and "cannabis-derived terpenes."

For operators building premium extract brands, the sourcing question is a brand integrity question. A product labeled with a cultivar name implicitly promises the experience of that cultivar. Botanical terpenes cannot deliver that promise — no matter how well they're blended.

The Extraction Challenge

The reason botanical terpenes dominate the market isn't preference — it's practicality. Capturing CDTs at scale, with high purity and without degradation, has historically been difficult and expensive. Most cannabinoid extraction processes destroy terpenes in the process.

Cryogenic pre-process extraction changes that equation. By capturing terpenes before cannabinoid extraction begins — using liquid nitrogen rather than heat or solvents — the STX-90 produces strain-specific CDT isolates at >99% purity from the same biomass operators are already processing.